Der Einfluß polymerer Kieselsäuren auf die renale SiO2-Ausscheidung beim Menschen

Langendorf, H.; Lang, Konrad

doi:10.1007/bf02022508

Cited by 1 publication

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentrations leading to 50% reduction cell viability increased with particle size. Morishige et al (2010) compared the cytotoxicity of SAS of various particle sizes (30,50,70, 300 or 1,000 nm) against differentiated THP-1 human macrophage-like cells and concluded that 30-70 nm particles did not induce cell death but 300 and 1,000 nm particles showed cytotoxicity. According to the authors, this was due to generation of reactive oxygen species.…”

Section: Other Studies Effects On Humansmentioning

confidence: 99%

“…In humans, there was little indication of absorption of SAS after ingestion; however, silicon dioxide (of unknown origin) was occasionally found in human liver and spleen tissues. Some studies reported that less than 0.5% of silicon orally applied as silicon dioxide (1,250 mg) was excreted via urine but urinary silicon was always within the range of normal physiological variation (Degussa AG, 1966 Documentation provided to EFSA n. 18); Lang, 1966 Documentation provided to EFSA n. 50); Langendorf and Lang, 1967).…”

Section: Sasmentioning

confidence: 99%

“…For precipitated silica, individual mean excretion rates ranged from 16 to 71 mg/day in the pretest phase and from 20 to 81 mg/day in the post-treatment. The authors concluded that the changes in silicon excretions were within the range of normal physiological variation, and there was little indication of absorption of silica after ingestion (Degussa AG, 1966 (Documentation provided to EFSA n. 18); Lang, 1966 (Documentation provided to EFSA n. 50); Langendorf and Lang, 1967). The Panel noted that the administered dose was very high and that excretion in faeces was not measured.…”

Section: Human Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Re‐evaluation of silicon dioxide (E 551) as a food additive

Younes¹,

Aggett²,

Aguilar³

et al. 2018

EFS2

View full text Add to dashboard Cite

The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion re-evaluating the safety of silicon dioxide (E 551) when used as a food additive. The forms of synthetic amorphous silica (SAS) used as E 551 include fumed silica and hydrated silica (precipitated silica, silica gel and hydrous silica). The Scientific Committee on Food (SCF) established a group acceptable daily intake (ADI) 'not specified' for silicon dioxide and silicates. SAS materials used in the available biological and toxicological studies were different in their physicochemical properties; their characteristics were not always described in sufficient detail. Silicon dioxide appears to be poorly absorbed. However, silicon-containing material (in some cases presumed to be silicon dioxide) was found in some tissues. Despite the limitations in the subchronic, reproductive and developmental toxicological studies, including studies with nano silicon dioxide, there was no indication of adverse effects. E 551 does not raise a concern with respect to genotoxicity. In the absence of a long-term study with nano silicon dioxide, the Panel could not extrapolate the results from the available chronic study with a material, which does not cover the full-size range of the nanoparticles that could be present in the food additive E 551, to a material complying with the current specifications for E 551. These specifications do not exclude the presence of nanoparticles. The highest exposure estimates were at least one order of magnitude lower than the no observed adverse effect levels (NOAELs) identified (the highest doses tested). The Panel concluded that the EU specifications are insufficient to adequately characterise the food additive E 551. Clear characterisation of particle size distribution is required. Based on the available database, there was no indication for toxicity of E 551 at the reported uses and use levels. Because of the limitations in the available database, the Panel was unable to confirm the current ADI 'not specified'. The Panel recommended some modifications of the EU specifications for E 551.

show abstract

Section: Other Studies Effects On Humansmentioning

confidence: 99%

Section: Sasmentioning

confidence: 99%

Section: Human Studiesmentioning

confidence: 99%

See 1 more Smart Citation